Drugs / Apalulizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07306273 | Dec 2025 → Aug 2027 expected | pancreatic adenocarcinoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07306286 | Dec 2025 → Aug 2027 expected | pancreatic adenocarcinoma | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apalulizumab | “A Single-Arm, Open-Label Clinical Study of Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab) for the Treatment of Locally Advanced Pancreatic...” NCT07306286 ↗1“Dual-Function Antibody PD-1/CTLA-4 (Apalulizumab)” NCT07306273 ↗ |
| Route | Intravenous | “Dual-Function Antibody PD-1/CTLA-4 iv. injection” NCT07306273 ↗ |